U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06850454) titled 'Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy' on Nov. 07, 2024.
Brief Summary: A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy
Study Start Date: Jan. 10
Study Type: INTERVENTIONAL
Condition:
Chemotherapy Induced Nausea and Vomiting
Intervention:
DRUG: olanzapine
olanzapine 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
DRUG: Placebo
placebo 5 mg oral prior to chemotherapy on day 1 and daily on day 2-4
Recruitment Status: RECRUITING
Sponsor: Mahidol University
Information provided by (Responsible Party): suthin...